Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Other

21 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    Miscellaneous

    VICCPED1544

    12/14/2015

    Michigan Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository

    Basic Science

    Miscellaneous

    VICCMD1564

    11/23/2015

    Acquisition and Research Use of Biospecimens in Cancer Patients

    Basic Science

    Miscellaneous

    VICCBIO0478

    03/31/2004

    Donating Tissues for Research

    Diagnostic

    Miscellaneous

    VICCSAR1458

    04/22/2015

    F18-FES PET/CT Imaging of Desmoid Tumors

    Health Services Research

    Miscellaneous

    VICCPED15132

    03/16/2016

    Assessing Literacy and Numeracy in Pediatric Oncology Parents

    Other

    Miscellaneous

    COGAPEC14B1

    01/20/2016

    The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

    Other

    Miscellaneous

    VICCMEL15138

    06/23/2015

    Survivorship in Patients Receiving Immune Checkpoint Inhibitors

    Other

    Lung
    Miscellaneous
    Small Cell

    VICCMD1494

    10/31/2014

    Specimen Collection under Clinical Protocol 06-C-0213 for Generation of Patient-Derived Models

    Other

    Miscellaneous

    VICCPED0710

    03/16/2007

    Long Term Effects for Childhood Cancer Survivors

    Prevention

    Other

    CTSUHNE1311-M

    09/03/2013

    A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence

    Supportive Care

    Miscellaneous

    VICCREACH1525

    05/11/2015

    Navigated Early Survivorship Transition (NEST) Project

    Supportive Care

    Miscellaneous

    VICCBMT14119

    01/21/2015

    A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

    Supportive Care

    Miscellaneous

    VICCBMT14118

    01/21/2015

    A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract

    Treatment

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell
    Uterine

    VICCPHI1634

    08/30/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    Hematologic
    Leukemia
    Lung
    Miscellaneous
    Small Cell

    VICCHEMP1615

    07/21/2016

    A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

    Treatment

    Lymphoma
    Miscellaneous

    VICCPHI1616

    06/08/2016

    A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

    Treatment

    Colon
    Head/Neck
    Liver
    Lung
    Miscellaneous
    Neuro-Oncology
    Rectal
    Sarcoma
    Thyroid

    VICCMD15110

    04/05/2016

    A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

    Treatment

    Other

    ECOGEAY131-M

    07/16/2015

    Molecular Analysis for Therapy Choice

    Treatment

    Other

    INCBBRE268-M

    11/21/2014

    INCB 18424-268 A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic HER2-negative Breast Cancer (

    Treatment

    Other

    CTSUBREA011106-M

    11/01/2014

    BRE A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study

    Treatment

    Other

    CTSUMM1A11-M

    02/12/2014

    MM E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)


    Print this page for your doctor